Welcome to our dedicated page for Tonix Pharmaceut SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tonix Pharmaceuticals Holding Corp. SEC filings document a commercial-stage biotechnology company with Nasdaq-listed common stock and programs spanning CNS disorders, immunology, infectious diseases and rare diseases. Recent Form 8-K reports cover Regulation FD disclosures, selected operating and financial results, capital-structure information, commercial arrangements for TONMYA, and clinical or preclinical updates for programs such as TNX-4800, TNX-1700 and TNX-1900.
The company’s proxy and annual meeting filings describe board elections, shareholder voting results, equity incentive plan approvals, executive compensation matters and other governance subjects. Tonix filings also provide formal records of material events, exhibit-based press releases and presentations, risk-related disclosures, registered securities and public-company reporting obligations.
Tonix Pharmaceuticals Holding Corp. director Richard H. Bagger received a grant of stock options as part of his compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share. These options were granted under the company’s 2026 Stock Incentive Plan and vest on the earlier of one year after the grant date or the 2027 Annual Meeting of Stockholders. Following this award, he holds 22,700 derivative securities directly.
Tonix Pharmaceuticals Holding Corp. reported that director Carolyn E. Taylor received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share and expire on May 12, 2036.
The award was granted under Tonix’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the May 12, 2026 grant date and the company’s 2027 Annual Meeting of Stockholders. Following this grant, Taylor holds stock options for 22,700 shares as reported in this filing.
Tonix Pharmaceuticals reported first quarter 2026 results showing early commercial traction for TONMYA alongside higher spending and losses. Net product revenue rose to approximately $6.9 million, up from $2.4 million a year earlier, driven by TONMYA, Zembrace SymTouch and Tosymra.
Net revenue from TONMYA was about $3.7 million in the quarter, with roughly 2,145 prescribers, 3,588 patients starting treatment and ~5,400 prescriptions filled in the first full quarter since launch. Research and development expenses increased to about $18.2 million and selling, general and administrative expenses to $28.6 million as the company invested in its pipeline and commercial infrastructure.
Tonix posted a net loss available to common stockholders of approximately $40.2 million, or $2.93 per share, compared with a loss of about $16.8 million, or $2.84 per share, in the prior-year quarter. Cash and cash equivalents were roughly $185.5 million as of March 31, 2026, and management believes existing cash plus second-quarter equity proceeds will fund operations into early second quarter 2027.
Tonix Pharmaceuticals reported sharply higher Q1 2026 net product revenue of $6.9 million, up from $2.4 million a year earlier, driven mainly by the launch of fibromyalgia drug TONMYA and growth in migraine products Zembrace SymTouch and Tosymra.
Despite this growth, Tonix posted a larger net loss of $40.2 million versus $16.8 million in Q1 2025 as research and development spending rose to $18.2 million and selling, general and administrative costs increased to $28.6 million, reflecting commercialization and pipeline investments.
The company ended March 31, 2026 with $185.5 million in cash and cash equivalents and working capital of about $177.5 million, but disclosed that these resources, including additional equity raised in Q2 2026, are expected to fund operations only into early second quarter 2027, leading to a stated substantial doubt about its ability to continue as a going concern without new financing.
Tonix Pharmaceuticals Holding Corp. reported results of its annual shareholder meeting. Shareholders approved the 2026 Stock Incentive Plan, allowing equity-based awards to employees, directors and key consultants. They also authorized the Board, within two years of May 7, 2026, to implement one or more reverse stock splits at ratios between 1-for-2 and 1-for-250 of the then-outstanding common shares, with exact terms to be set later. Nine directors were elected and PricewaterhouseCoopers LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Tonix Pharmaceuticals Holding Corp. entered into an agreement with a leading group purchasing organization, effective May 1, 2026, that provides commercial insurance coverage for TONMYA to approximately 35 million U.S. lives, about 20% of roughly 177 million commercially insured individuals.
TONMYA, a first-in-class non-opioid analgesic and the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years, is also covered under Medicaid in 38 states for approximately 55 million beneficiaries, representing 73% of roughly 75 million Medicaid lives.
Tonix Pharmaceuticals released preliminary figures for the quarter ended March 31, 2026. Net revenue from Zembrace® SymTouch® and Tosymra® was about $3.2 million, up from $2.4 million for the same quarter in 2025, reflecting higher migraine-product sales.
Net revenue from TONMYA® was about $3.7 million in the quarter, following its November 2025 launch and $1.4 million of revenue through December 31, 2025. The company believes its March 31, 2026 cash resources plus $17.4 million of second-quarter 2026 equity-offering proceeds will fund planned operations and capital needs into the second quarter of 2027.
The company emphasized these results are unaudited, preliminary estimates prepared by management and subject to change as closing procedures are completed. Its independent auditor has not reviewed this data. Tonix currently expects to file its full Quarterly Report on Form 10-Q on or about May 11, 2026.
Tonix Pharmaceuticals reported new data and development plans for TNX-4800, a long-acting monoclonal antibody designed to prevent Lyme disease by targeting the OspA protein on Borrelia burgdorferi. The company presented Phase 1 results and program updates at the 4th Annual Ticks and Tickborne Diseases Symposium.
Phase 1, a randomized, double-blind, dose-escalation study in 44 healthy adults, found TNX-4800 to be generally safe and well tolerated, with no significant clinical or laboratory safety signals and mostly mild or moderate adverse events. Tonix plans a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study starting in the first half of 2027, pending FDA agreement, testing a fixed two-dose subcutaneous regimen given in Spring and two months later, aiming to prevent Lyme disease for six months after the initial dose.
Tonix Pharmaceuticals Holding Corp. filed a report describing new preclinical data on its immuno-oncology candidates TNX-1700 and TNX-4700 presented at the 2026 AACR Annual Meeting. Collaborators showed that a murine version of TNX-1700 reversed aging-associated gastric inflammation and attenuated tumor progression in aged mice.
A second study found TNX-1700 had dose-independent, linear pharmacokinetics in non-human primates and human FcRn/serum albumin transgenic mice, with all animals surviving without major weight loss. A third poster reported that TNX-4700, an anti-BTLA antibody, demonstrated potent, high-affinity binding and functional antagonism in vitro.
Tonix Pharmaceuticals Holding Corp. director and Chief Executive Officer Seth Lederman reported an indirect open-market purchase of 5,000 shares of common stock on March 31, 2026 through an IRA account. The weighted average purchase price was about $12.62 per share, from trades between $12.5699 and $12.625.
Following this transaction, the IRA account holds 20,001 shares indirectly, while Lederman also holds 4,005 shares directly and 1 share indirectly through Lederman & Co., an entity for which he may be deemed a control person.